Medicine Pathways, Guidelines And Position Statements

Expand / Collapse All

COVID-19

Information for vaccinators
Medicines for the treatment and prevention of COVID-19
Monitoring for medicines during COVID-19 pandemic

NCL

Camden and Islington NHS Foundation Trust

Depot or long-acting antipsychotic injections (approved by CIFT)

Managing medicines during the COVID-19 pandemic

Cardiovascular system (inc. DOACs)

Direct Oral Anticoagulants (DOACs)

The documents below have been agreed by the stakeholders working in North Central London and have been approved by the NCL Joint Formulary Committee (NCL JFC). They should be used to refer appropriate patients to his/her local anticoagulation clinic for initiation of anticoagulation.
Where appropriate, local anticoagulation clinics should add their own contact details on the relevant paperwork (i.e. referral proformas, notification and transfer of care forms)
Please note that these documents may be updated intermittently. Users are also reminded that the prescribing guidance is not definitive and that other sources such as the electronic medicines compendium (SPCs) should be used for the most recent drug information. This can be found at the following link: http://www.medicines.org.uk/emc/default.aspx

VTE: Choice of DOAC (Position Statement)

Other

Summary of Antiplatelet Options in Cardiovascular Disease
Sacubitril valsartan for heart failure position statement (NEL and NCL joint positioning)
Statin prescribing & lipid modification guideline
Stable angina prescribing guideline
Omega-3 Fatty Acids Position Statement
Guidance for the review of Omega-3 fatty acids
Guidance for the management of hypertriglyceridaemia

Respiratory system

Asthma adult inhaler choice
Discontinuation of Phyllocontin® (aminophylline) memo

The following COPD guideline has been produced by the Camden, Haringey and Islington Responsible Respiratory Prescribing Group and applies to organisations that are constituent members. It has not been ratified by the NCL Joint Formulary Committee and does not apply to all organisations in NCL.

Stable COPD Treatment Guideline

Infections

NICE and Public Health England (PHE) have brought together their information on managing common infections into a summary table. The North Central London Medicines Optimisation Committee (NCL MOC) support the use of the:

NICE/PHE Managing Common Infections summary table (hosted on BNF).

 

Fluoroquinolones safe prescribing Position Statement
Treatment of Infections due to Multi-Drug Resistant Gram Negative Pathogens

From 1 June, the Health Services Laboratories (HSL) microbiology laboratory will apply new antimicrobial susceptibility result definitions recommended by the European Committee on Antimicrobial Susceptibility (EUCAST). While the letters ‘S’, ‘I’ and ‘R’ are retained, the definitions for the letters ‘S’ and ‘I’ have changed.
Communication to clinicians: Changes to antibiotic susceptibility reporting
Standard and High Dose Antibiotic Dosing Regimens

Endocrine system

Type 2 diabetes

Antihyperglycaemic agents for Type 2 diabetes
Insulin for Type 2 diabetes

 

Diabetes meters (finger-prick testing)

Blood glucose and Ketone monitoring

 

Diabetes meters (flash glucose monitoring)

See ‘Flash glucose monitoring‘ page

 

Other

Liothyronine position statement

Endocrine system – Flash glucose monitoring

Use of Flash Glucose Monitoring in North Central London (includes FSL and FSL2)
Forms – for use by diabetes specialists (includes FSL and FSL2)
Information sheets – for patients and primary care (FSL only)
Training materials (FSL only)
Competencies (FSL only)